Urine (TP2)
MINOR
Recovery of urine radioactivity following centrifugation was complete, indicating no loss of drug‐related components during sample processing. The 0–24 h urine samples that were analyzed represented 97% of total cumulative radioactivity excreted in the urine. Minor qualitative differences in the urine radio profiles were observed across the 6 subjects. Figure Representative reconstructed HPLC‐radiochromatograms of urine and fecal extracts from a single subject following a single oral dose of [Unchanged daprodustat was not detected in the 0–24 h urine from any subject. The metabolite profile in urine was similar to that in plasma. Predominant radio peaks in urine were M3, M13, a coeluting peak of M2 and M33, and a coeluting peak of M5 and M14, accounting respectively for a mean of 16%, 17%, 16%, and 10% of urine radioactivity, or 3%, 3%, 3%, and 2% of the administered dose. Additional metabolites M4 and M6 each accounted for a mean of 8% and 6% of urine radioactivity, or 2% and 1% of the dose, respectively. All other metabolites (M9, M15, M22, M32), an unassigned radio peak B, and several minor metabolites and unassigned radio peaks were detected, individually at <5% of urine radioactivity (≤1% of dose). Mean radioactivity quantified in urine was approximately 87% of the total present.